MARKET

ADVM

ADVM

Adverum
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.270
-0.110
-4.62%
After Hours: 2.300 +0.03 +1.32% 18:22 07/30 EDT
OPEN
2.380
PREV CLOSE
2.380
HIGH
2.450
LOW
2.265
VOLUME
2.23M
TURNOVER
--
52 WEEK HIGH
19.25
52 WEEK LOW
2.255
MARKET CAP
222.31M
P/E (TTM)
-1.6779
1D
5D
1M
3M
1Y
5Y
Bionano (BNGO) to Report Q2 Earnings: What's in the Cards?
Zacks.com · 2d ago
75 Biggest Movers From Friday
Gainers The New Home Company Inc. (NYSE: NWHM) jumped 82.9% to settle at $8.89 on Friday after the company agreed to be acquired by funds managed by affiliates of Apollo Global Management for $9 per share in all-cash transaction.
Benzinga · 5d ago
Hot Stocks: RHI drives recruiters MAN, KFRC; low-cost retailers hit highs; UP goes down; VNE, NWHM get bought
champc/iStock via Getty Images While earnings dominated Wall Street conversation on Friday, a couple of other simmering themes exerted influence as well. For instance, the tight labor market helped drive
Seekingalpha · 07/23 21:26
Where Adverum Biotechnologies Stands With Analysts
Analysts have provided the following ratings for Adverum Biotechnologies (NASDAQ:ADVM) within the last quarter: Last 30 Days 1 Month Ago
Benzinga · 07/23 18:58
Xenetic Biosciences, Medigus leads healthcare gainers; ImmunoPrecise Antibodies, Adverum Biotechnologies among major losers
Gainers: Xenetic Biosciences XBIO +126%, Medigus MDGS+35%, Acorda Therapeutics ACOR +30%, NRx Pharmaceuticals NRXP +14%, Apollo Medical (AMEH) +13%.Losers: ImmunoPrecise Antibodies (IPA) -36%, Adverum Biotechnologies ADVM -23%, Chembio Diagnostics (CEMI) -...
Seekingalpha · 07/23 15:05
Adverum plunges as analysts turn bearish citing setback for diabetic macular edema drug
Shidlovski/iStock via Getty Images Trading ~18.3% lower in the early trading, Adverum Biotechnologies (ADVM) has extended the post-market losses after the company announced the discontinuation of its plans to develop ADVM-022 for
Seekingalpha · 07/23 12:45
DiDi Global, KE Holdings, TAL Education among premarket losers' pack
New Oriental Education & Technology EDU -63% on report China considering tutoring companies become non profits.Gaotu Techedu GOTU -59% on report China considering tutoring companies become non profits.TAL Education TAL -53% on report China considering tuto...
Seekingalpha · 07/23 12:26
--Goldman Sachs Downgrades Adverum Biotechnologies to Neutral From Buy, Adjusts PT to $3 From $10
MT Newswires · 07/23 11:56
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADVM. Analyze the recent business situations of Adverum through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADVM stock price target is 3.875 with a high estimate of 6.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 191
Institutional Holdings: 105.83M
% Owned: 108.07%
Shares Outstanding: 97.93M
TypeInstitutionsShares
Increased
44
6.29M
New
8
286.31K
Decreased
51
4.43M
Sold Out
26
1.15M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
-0.24%
Key Executives
Non-Executive Chairman/Independent Director
Patrick Machado
President/Chief Executive Officer/Director
Laurent Fischer
Chief Financial Officer
Christopher DeRespino
Chief Operating Officer
Peter Soparkar
Chief Technology Officer
Angela Thedinga
Chief Scientific Officer
Brigit Riley
Vice President
Jon Williams
Other
Julie Clark
Director
Mehdi Gasmi
Independent Director
Mark Lupher
Independent Director
James Scopa
Independent Director
Dawn Svoronos
Independent Director
Reed Tuckson
Independent Director
Scott Whitcup
Independent Director
Thomas Woiwode
No Data
About ADVM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. The Company is evaluating its gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. It has collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products (AVA-311) for ophthalmic diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its capabilities include clinical development, vector discovery, and in-house manufacturing, specifically in process development, assay development and current Good Manufacturing Practices (cGMP) quality control.

Webull offers kinds of Adverum Biotechnologies Inc stock information, including NASDAQ:ADVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADVM stock methods without spending real money on the virtual paper trading platform.